CRBP — Corbus Pharmaceuticals Holdings Inc · catalysts, narrative & risks

Company Profile

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical-stage biotech headquartered in Norwood, Massachusetts, focused on oncology and obesity. Its pipeline includes CRB-701 (a Nectin-4-targeting antibody-drug conjugate), CRB-601 (an anti-integrin monoclonal antibody blocking TGFβ), and CRB-913 (an oral, peripherally restricted CB1 receptor inverse agonist for obesity). The company has no marketed products and no stable revenue stream [10], [16], [19]. As of late October 2026 the stock had a market capitalization of ~$81.6M, a 52-week range of $3.87–$17.24, and a beta of 2.79 [15].

Key Recent Catalysts (last ~1–3 months, as of 2026-11-01)